Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule
Completed · Phase 1
Conditions studied: Lung Cancer
In brief
This study will look at how the \[18\]FACBC goes into the lung nodules. This will hopefully lead to the development of better imaging techniques to look at lung nodules. \[18\]FACBC is not approved by the FDA (Food and Drug Administration). This study will help to determine if it should be approved by the FDA.
Key facts
- Study ID
- NCT01502670
- Run by
- Emory University
- People needed
- 10
- Starts
- 2009-05-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2013-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must be 18 years of age or older.
- Patients with a history of cancer who have a solitary pulmonary nodule between 1-3 cm in short axis with clinical and CT characteristics warranting surgical removal (see below).
- Clinical, laboratory, or diagnostic imaging findings on CT or 18F-FDG PET-CT do not suggest the possibility of the SPN being part of a metastatic process.
- Ability to lie still for PET scanning
- Patients must be able to provide written informed consent.
You may not qualify if…
- Age less than 18.
- Active carcinoma with known metastatic disease.
- Size of primary lesion less than 1 cm or greater than 3 cm
- Not a candidate for surgical resection or biopsy based upon clinical condition or discovery of metastatic disease which would preclude surgical therapy.
- Inability to lie still for PET scanning
- Cannot provide written informed consent
Where it is running
- Emory University — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.